Nivolumab

A randomized phase 3 trial designed to evaluate the addition of nivolumab to standard therapy for certain patients with newly diagnosed glioblastoma multiforme failed to meet one of its primary endpoints of PFS.

Nivolumab in combination with brentuximab vedotin appeared safe and induced high antitumor activity among patients with relapsed or refractory primary mediastinal B-cell lymphoma, according to results of the phase 2 CheckMate 436 trial published in Journal of Clinical Oncology.

One of the hot topics at this year’s ASCO Annual Meeting was broadening eligibility criteria to increase clinical trial access and enrollment.

The FDA granted breakthrough therapy designation to bempegaldesleukin in combination with nivolumab for initial treatment of unresectable or metastatic melanoma.

Immune therapy combinations have made a tremendous impact on life expectancy and induced long-term remissions. Targeted therapy has also made big strides in improving outcomes. Cancer genomics has the potential to help us customize therapy in the future.

In 2017, the positive results of two trials — CheckMate-214 and CABOSUN — garnered a great deal of attention and discussion, and prompted many in the field to claim that a revolution is underway in the management of patients with metastatic renal cell carcinoma. To better understand the implications of these trials, Healio spoke with Neeraj Agarwal, MD, director of the genitourinary oncology program and associate professor of medicine at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, who discussed the key findings, and shared his thoughts on how the landscape of metastatic renal cell carcinoma therapies may change in the coming years.

Findings from a recent retrospective study demonstrated a multiyear decline in the population-level mortality of melanoma. This decline has been associated with the FDA approval of 10 novel treatments for metastatic melanoma since 2011.

Healio spoke with Jacob Sands, MD, a medical oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about promising immunotherapeutic approaches currently being studied in small cell lung cancer.

Healio spoke with Jacob Sands, MD, a medical oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about advancements in the understanding of the molecular biology of small cell lung cancer.

Healio spoke with Jacob Sands, MD, a medical oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about treatment options for metastatic small cell lung cancer.